Taken together, our data demonstrate that in vitro rapamycin treatment generates CD8+ CAR T cells with enhanced ability to infiltrate into tumor islets, leading to a better control of tumor growth in two preclinical solid tumor models. This evidence concerns the gene CD8A and neoplasm.